African Medical Invest (LON:AMEI), the company that operates medical centres in Africa, said it was set to make its fourth draw down of funds from an equity line agreement with Harbinger Capital Partners Master Fund I. The move will take Harbinger's overall interest in the company to 43.56% and provide approximately US$2.42m to help AMI consolidate its position as a provider of private hospitals, Well Woman Clinics and trauma centres in Africa. AMI's facilities now include hospitals and Well Woman Clinics in Dar es Salaam and Maputo, the Trauma Centre in Harare, which is now being upgraded to a 20 bed hospital expected to open later in the year, and Airport Medical & Travel Vaccination Centres at Johannesburg International Airport and Cape Town International Airport.

Allergy Therapeutics (LON:AGY), the specialist allergy vaccination group, said it expected to report revenues of £40.7m when it published its full year results on September 20, up from £37.8m last year. Significantly, and for the first time as a public company, Allergy Therapeutics is expecting to post an operating profit against a loss of £6.2m in 2009. CEO, Manuel Llobet, said that posting a maiden operating profit would be a landmark in the company's performance.

Angel Biotechnology Hldgs (LON:ABH), the specialist contract manufacturer of advanced biologics, said it had made a net profit of £106,737 in the six months to June 30 and was on course to continue the trend for the full year. Angel signed eight new contracts, together worth £3.3m, during the period and slashed its net liabilities from to £100,000 from £1.6m last December. More than 92% of 2010 budgeted business has been signed and almost 40% of the business budgeted for 2011. Separately, the company said it had agreed terms to pay down an outstanding £486,976 loan from EPhaG AS with cash instalments set to finish in June 2011.

Elsewhere, Deltex Medical Group (LON:DEMG), the specialist in oesophageal Doppler monitoring (ODM), said it had made significant progress in all of its key markets during the first half of the year as it moved towards its goal of establishing the use of the CardioQ-ODM system as a standard of care in the management of patients undergoing major surgery. Sales were higher than in the first half of 2009 in all key markets and increased overall by more…

Unlock the rest of this article with a 14 day trial

Already have an account?
Login here